Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
26 hedge funds and large institutions have $81.9M invested in Sierra Oncology, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
22% more capital invested
Capital invested by funds: $67M → $81.9M (+$14.9M)
18% more funds holding
Funds holding: 22 → 26 (+4)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$433K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$431K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$120K |
| 4 |
Renaissance Technologies
New York
|
+$118K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$72.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$1.39M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$229K |
| 3 |
SCM
Sio Capital Management
New York
|
-$151K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$54.4K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$30K |
SRRA Hedge Fund Activity: Q2 2020 in Review
26 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2020, worth a combined $81.9M — up 22% from $67M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SRRA positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $433K. The largest seller was VR Adviser, cutting an estimated $1.39M.
- 26 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2020, up from 22 in Q1 2020.
- Funds reported $81.9M of Sierra Oncology, Inc. Common Stock stock for Q2 2020, up 22% quarter-over-quarter.
- 6 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2020 and 2 closed out, a net change of +4 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2020 was Bridgeway Capital Management, an estimated $433K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2020 was VR Adviser, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2020.